These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 10051056)

  • 1. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis.
    van Lent-Evers NA; Mathôt RA; Geus WP; van Hout BA; Vinks AA
    Ther Drug Monit; 1999 Feb; 21(1):63-73. PubMed ID: 10051056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of active TDM in elderly patients treated with aminoglycosides].
    Leon-Djian CB; Bourguignon L; Späth HM; Maire P
    Therapie; 2011; 66(5):445-52. PubMed ID: 22031689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Level of evidence for therapeutic drug monitoring of aminoglycosides].
    Venisse N; Boulamery A;
    Therapie; 2011; 66(1):39-44. PubMed ID: 21466776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring.
    Slaughter RL; Cappelletty DM
    Pharmacoeconomics; 1998 Oct; 14(4):385-94. PubMed ID: 10344906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients.
    Cies JJ; Varlotta L
    Pediatr Pulmonol; 2013 Dec; 48(12):1190-4. PubMed ID: 23281228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Drug Monitoring Coupled With Bayesian Forecasting Could Prevent Vancomycin-Associated Nephrotoxicity in Renal Insufficiency Patients: A Prospective Study and Pharmacoeconomic Analysis.
    Zhang Y; Wang T; Zhang D; You H; Dong Y; Liu Y; Du Q; Sun D; Zhang T; Dong Y
    Ther Drug Monit; 2020 Aug; 42(4):600-609. PubMed ID: 32097248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.
    Fernández de Gatta MD; Calvo MV; Hernández JM; Caballero D; San Miguel JF; Domínguez-Gil A
    Clin Pharmacol Ther; 1996 Sep; 60(3):332-40. PubMed ID: 8841156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost considerations in therapeutic drug monitoring of aminoglycosides.
    Bertino JS; Rodvold KA; Destache CJ
    Clin Pharmacokinet; 1994 Jan; 26(1):71-81. PubMed ID: 8137600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic dosing of aminoglycosides: a controlled trial.
    Bartal C; Danon A; Schlaeffer F; Reisenberg K; Alkan M; Smoliakov R; Sidi A; Almog Y
    Am J Med; 2003 Feb; 114(3):194-8. PubMed ID: 12637133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.
    Boyer A; Gruson D; Bouchet S; Clouzeau B; Hoang-Nam B; Vargas F; Gilles H; Molimard M; Rogues AM; Moore N
    Drug Saf; 2013 Apr; 36(4):217-30. PubMed ID: 23508544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring.
    Croes S; Koop AH; van Gils SA; Neef C
    Eur J Pharm Sci; 2012 Jan; 45(1-2):90-100. PubMed ID: 22094306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is therapeutic drug monitoring (TDM) in paediatric patients necessary?].
    Prokopczyk J; Piekarczyk A; Kaminska E
    Med Wieku Rozwoj; 2001; 5(2):149-55. PubMed ID: 11679679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists: analysis of 7-year data].
    Xu G; Chen E; Mao E; Che Z; He J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Jul; 30(7):640-645. PubMed ID: 30045790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Characteristics and Limited Sampling Strategies for Therapeutic Drug Monitoring of Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections.
    Kim EJ; Oh J; Lee K; Yu KS; Chung JY; Hwang JH; Nam EY; Kim HS; Kim M; Park JS; Song KH; Kim ES; Song J; Kim HB
    Ther Drug Monit; 2019 Feb; 41(1):102-106. PubMed ID: 30299430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of vancomycin therapeutic drug monitoring on patient care.
    Welty TE; Copa AK
    Ann Pharmacother; 1994 Dec; 28(12):1335-9. PubMed ID: 7696720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring.
    Nicolau DP; Wu AH; Finocchiaro S; Udeh E; Chow MS; Quintiliani R; Nightingale CH
    Ther Drug Monit; 1996 Jun; 18(3):263-6. PubMed ID: 8738765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of individualized pharmacokinetic dosing on patient outcome.
    Whipple JK; Ausman RK; Franson T; Quebbeman EJ
    Crit Care Med; 1991 Dec; 19(12):1480-5. PubMed ID: 1959366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.